Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Provider Statement: This continuing medical education activity is provided by 
.
Support Statement: This activity is supported by an independent educational grant from Merck & Co., Inc.
Target Audience: The intended audience for the activities is medical oncologists, clinical researchers, and other health care professionals involved in the treatment of patients with melanoma.
Learning Objectives: Upon successful completion of this educational activity, participants should be better able to:
- Compare and contrast available and emerging immunotherapies for the treatment of metastatic melanoma based on mechanism of action, clinical safety and efficacy, and recommended usage.
- Evaluate single-agent versus combination immunotherapy-based treatment regimens for the frontline management of metastatic melanoma.
Activity Chair:
Mario Sznol, MD
Co-director, Yale Skin SPORE
Associate Chief, Section of Medical Oncology
Yale-Smilow Cancer Center
Professor of Medicine (Medical Oncology)
Yale School of Medicine
New Haven, CT
Faculty:
Omid Hamid, MD
Chief, Translational Research and Immuno-Oncology
Director of Melanoma Program
The Angeles Clinic and Research Institute
Los Angeles, CA
Reviewers:
Jason J. Luke, MD, FACP
Ronald A. Codario, MD, FACP, FNLA, CCMEP
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, January 12, 2016, through January 11, 2017.
How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the presentations, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Activity Chair and Faculty member report the following relationship(s):
Mario Sznol, MD
Contracted Research: AstraZeneca/MedImmune, Bristol-Myers Squibb, Genentech/ Roche, Immunocor, Kyowa-Kirin, Merck, Pfizer
Consulting Fee: Anaeropharma, Astellas-Agensys, Astra-Zeneca/MedImmune, Bristol-Myers Squibb, Genentech/Roche, Immune Design, Immunova, Kyowa-Kirin, Merus, Nektar, Neostem, Novartis, Pfizer, Pierre-Fabre, Prometheus, Seattle Genetics
Ownership Interest: Amphivena, Adaptive Biotechnologies
Scientific Advisory Board: Adaptive Biotechnologies, Amphivena, Lion Biotechnologies, Symphogren
Omid Hamid, MD
Consulting: Amgen, Bristol-Myers Squibb, Novartis, Roche
Speaker Bureau: Bristol-Myers Squibb, Genentech, Novartis
Contracted Research: AstraZeneca, Bristol-Myers Squibb, Celldex, Genentech, Immunocore, Incyte, Merck, Merck-Serano, MedImmune, Novartis, Pfizer, Rinat, Roche
Reviewers report the following relationship(s):
Jason J. Luke, MD, FACP
Consulting Fee: Amgen
Contracted Research: BBI Therapeutics, Bristol-Myers Squibb, Celldex,
Genentech, Incyte, MedImmune, Merck
Ronald A. Codario, MD, FACP, FNLA, CCMEP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2016 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com